Day One Q4 Prescription Volumes Increase to 1,394
Q4 prescription volumes increased to 1,394. "2025 was a seminal year for Day One, marked by significant achievements across every pillar of our organization. By maintaining our strong commercial execution, leveraging our expertise to extend into additional rare cancers, and steadily advancing our early-stage pipeline, we are delivering on our mission to bring new medicines to people of all ages with life-threatening diseases," said Jeremy Bender, chief executive officer of Day One. "The commercial momentum we've established for Ojemda and the important upcoming clinical data updates across our full pipeline position us for strong growth in 2026 and beyond."
